P
ProHub
English 简体中文 繁體中文
Medium Profitability Product Launch Market Entry

Fringe Science

#Healthcare
ProHub Comment

This case combines market analysis with clinical/qualitative factors to guide a high-stakes R&D investment decision. The candidate must balance quantitative profitability calculations against qualitative healthcare considerations (safety/efficacy profiles, formulary status, competitive positioning) and demonstrate how pricing strategy significantly impacts market share and formulary access in pharmaceutical markets.

Estimated Time 27 minutes
Difficulty Medium
Source Duke
10 / 100
Massive Dynamic is a multi-national pharmaceutical company. One of their assets, Cortexiphan, is an anti-infective that successfully treats three major types of hospital-born illness and is currently in Phase II clinical trials. Unfortunately, Massive Dynamic only has the capital to finance a Phase III clinical trial for one of the three illnesses with Cortexiphan treats. Walter Bishop, Chief Medical Officer of Massive Dynamic, has enlisted your help to decide which of the three possible indications for cortexiphan they should pursue to maximize profits over a five year-period post-launch.

Clarifying Information

  1. Drug is only likely to be approved in the US at this time
  2. Drug will be sold directly to hospitals by Massive Dynamic; therefore, no need to consider distribution channel costs, etc.
  3. No need to calculate based on NPV, just do total over five years w/out discounting
  4. Provide Exhibit 1 when asked about market size and/or competition
  5. Provide Exhibit 2 when asked about development costs or clinical profile
  6. Provide Exhibit 3 after an initial indication selected and pricing prompt given
Mock Interview
Interviewer

Massive Dynamic is a multi-national pharmaceutical company. One of their assets, Cortexiphan, is an anti-infective that successfully treats three major types of hospital-born illness and is currently in Phase II clinical trials. Unfortunately, Massive Dynamic only has the capital to finance a Phase III clinical trial for one of the three illnesses with Cortexiphan treats. Walter Bishop, Chief Medical Officer of Massive Dynamic, has enlisted your help to decide which of the three possible indications for cortexiphan they should pursue to maximize profits over a five year-period post-launch.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

Massive Dynamic must choose between three indications for Cortexiphan to advance to Phase III trials. The case requires analyzing market size, competition, clinical profiles, development costs, and success probabilities to identify the most profitable indication, then optimizing pricing strategy to balance formulary access against revenue per dose.

Key Insights:

  1. Aspergillosis offers the best risk-adjusted returns ($4.75B expected profit) despite middle market size, due to superior clinical profile enabling market leadership and 50% trial success rate
  2. Candidiasis has largest market ($25B) but poor safety profile limits market share to 10%, making it unviable despite high trial success probability
  3. Premium pricing ($15) generates highest total profits ($28B) by capturing higher per-unit revenue despite lower formulary status, outweighing discount strategy’s volume advantage
  4. Healthcare cases require integrating clinical/formulary realities with financial analysis—candidate must recognize that pricing affects access and adoption patterns differently than traditional B2B markets
  5. Expected value framework properly incorporates trial failure risk, showing why Aspergillosis ($4.75B expected) beats Candidasis ($3.5B expected) despite latter’s higher success probability